The Exploratory Study About the Effect of Using Double Filtration Plasmapheresis (DFPP) Removing Inflammatory Cytokines, Lipids and Toxic Metal Ions in Peripheral Blood in Adults

Launched by SHANGHAI CELL THERAPY GROUP CO.,LTD · Jan 16, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a treatment called Double Filtration Plasmapheresis (DFPP). This procedure aims to improve health in adults by removing harmful substances from the blood, such as inflammatory proteins, fats, and toxic metal ions. Researchers believe that by cleaning the blood in this way, DFPP may help boost the body's immune system and overall well-being.

To participate, individuals must be between 18 and 85 years old and able to give consent. Those with high blood lipid levels or cholesterol may be included, but people with serious liver or kidney issues, heart problems, certain types of tumors, or who are pregnant or breastfeeding cannot take part. The trial is currently not recruiting participants, but once it starts, those who qualify can expect to undergo the DFPP treatment and will be closely monitored for any changes in their health.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Male/females of 18 to 85 years of age. For Group B, subjects should have elevated blood lipid or cholesterol, which could be a. hyperlipidemia; b. higher than the normal range but not high enough to be diagnosed as hyperlipidemia. Able to provide written Informed Consent. Able to follow verbal and written study directions.
• Exclusion Criteria:
• • Have sever liver and kidney dysfunction. Have cardiopulmonary insufficiency. Have solid or blood tumor. Pregnancy or breastfeeding women.